Adaptive Biotechnologies

The five-year-old firm recently completed a clinical trial of the real-time PCR-based test, called ProALL-BM, on patients from a European National Registry Study.

Some of the biggest players in the life science tools and diagnostics industries including Danaher, Agilent, and Hologic presented on day two of the conference, discussing plans for 2018.

The companies are planning to develop individual disease diagnostics, and then a universal diagnostic from a single blood test.

Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.

Adaptive will work with NCI's Cancer Therapy Evaluation Program to use its ImmunoSeq platform for biomarker discovery in clinical trials. 

The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.

The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology. 

Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.

Adaptive aims to commercialize and scale its techniques to identify immune signatures in other infectious diseases, autoimmune disorders, and even cancer.

Pages

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.